Linda Busche, Author at Pulmonary Hypertension Association

PHA Statement on CADD-MS3 and Subcutaneous Treprostinil for Health Care Professionals

PHA Statement on CADD-MS3 and Subcutaneous Treprostinil for Health Care Professionals

Linda Busche2022-12-19T13:59:12-05:00December 9th, 2022|

Since becoming aware of disruptions in CADD-MS3 (MS3) access earlier this year, the Pulmonary Hypertension Association (PHA) has been meeting with stakeholders and advocating on behalf of health care professionals and patients. To date, PHA has met with ICU Medical (device manufacturer); United Therapeutics Corporation (Remodulin); Liquidia (generic treprostinil); and Accredo Specialty Pharmacy. The

Remembering Rino Aldrighetti

Linda Busche2022-12-12T12:59:47-05:00September 2nd, 2022|

With great sadness, the Pulmonary Hypertension Association announces the death of Rino Aldrighetti, who led PHA for nearly two decades. Rino, who died May 30, was the first PHA employee, hired in 1999 as part-time executive director. He soon became full-time and later was promoted to president and CEO. He retired in 2016.

Advisory: Reproductive Health and Pulmonary Hypertension

Linda Busche2022-07-01T13:17:02-04:00May 25th, 2022|

Pregnancy is considered high risk for people with pulmonary hypertension because their heart and lungs can’t easily adjust to the demands of pregnancy and childbirth.

About Linda Busche

Title